News >

Grothey Grapples With Treatment Options in mCRC

Caroline Seymour
Published: Tuesday, Jun 26, 2018

Axel Grothey, MD

Axel Grothey, MD
It is still debatable which EGFR or VEGF inhibitors provide the greatest benefit when added to chemotherapy in the first-line setting of metastatic colorectal cancer (mCRC), but the identification of RAS, BRAF, and microsatellite instability (MSI) has helped physicians to refine treatment decisions.

State of the Science Summit™, Grothey, an oncologist at Sanford Burnham Cancer Center, discussed sidedness and first- and second-line treatments for patients with mCRC.

OncLive: Please provide an overview of your presentation on mCRC.

Grothey: I spoke about how to integrate molecular markers into the choice for first-line treatment of patients with CRC. We all intuitively look at patient and tumor characteristics, as well as patient wishes when we choose first-line treatment and the intensity of treatment, but more molecular markers have become available. [We’re using markers] like RAS and BRAF mutation status and, more recently, mismatch repair deficiency or MSI-H status to select which treatments we should offer patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication